Impact of CYP2C19 loss-of-function variants on outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and study design of the WOEST-3 genetic substudy
Background: The impact of CYP2C19 loss-of-function (LOF) variants on clopidogrel efficacy in atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) remains uncertain. While clopidogrel is the preferred P2Y12 inhibitor in combination with oral anticoagulants, approximately one-third of pat...